Contrast induced nephropathy epidemiology and demographics

Revision as of 14:24, 10 March 2014 by Rim Halaby (talk | contribs) (→‎Overview)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Contrast Induced Nephropathy Microchapters

Home

Patient Information

Overview

Definition

Historical Perspective

Pathophysiology

Differentiating Contrast induced nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Contrast induced nephropathy epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Contrast induced nephropathy epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Contrast induced nephropathy epidemiology and demographics

CDC on Contrast induced nephropathy epidemiology and demographics

Contrast induced nephropathy epidemiology and demographics in the news

Blogs on Contrast induced nephropathy epidemiology and demographics

Directions to Hospitals Treating Contrast induced nephropathy

Risk calculators and risk factors for Contrast induced nephropathy epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]

Overview

Incidence of CIN in the general population have been reported to be 0.6–2.3%.[1] It is considered to be the third most common cause of renal failure with an overall mortality rate of 19.4%[2] The incidence of CIN among patients undergoing PCI is approximately 7%.[3]

Epidemiology and Demographics

Although many regulations and precautions have been followed in the care of hospitalized patients, renal function deterioration remains a common event, the rate of nephropathy following exposure to CM, used in diagnostic and interventional studies differs according to the definition used, and also depend on other variables such as the type of radiology procedure performed, the dose and type of contrast agent administered. Incidence found to be 14.5% in a large epidemiological study[4], in other studies which define CIN as > 25% increase in serum creatinine levels over baseline in the first 5 days, Rates may vary according to the presence of risk factors. Patients with diabetes has been reported to be 9–40% in patients with mild-to-moderate chronic renal insufficiency, and 50–90% in those with severe chronic renal insufficiency.[5] [6] An overall incidence of CIN in the general population is reported to be 0.6–2.3%.[1] The overall mortality rate was 19.4% and was similar among patients for all causes of renal insufficiency, except sepsis.[2]

References

  1. 1.0 1.1 Lasser EC, Lyon SG, Berry CC (1997). "Reports on contrast media reactions: analysis of data from reports to the U.S. Food and Drug Administration". Radiology. 203 (3): 605–10. PMID 9169676.
  2. 2.0 2.1 Nash K, Hafeez A, Hou S (2002). "Hospital-acquired renal insufficiency". Am J Kidney Dis. 39 (5): 930–6. doi:10.1053/ajkd.2002.32766. PMID 11979336.
  3. Tsai TT, Patel UD, Chang TI, Kennedy KF, Masoudi FA, Matheny ME; et al. (2014). "Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry". JACC Cardiovasc Interv. 7 (1): 1–9. doi:10.1016/j.jcin.2013.06.016. PMID 24456715.
  4. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW (1997). "Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality". Am J Med. 103 (5): 368–75. PMID 9375704.
  5. Harkonen S, Kjellstrand CM (1977). "Exacerbation of diabetic renal failure following intravenous pyelography". Am J Med. 63 (6): 939–46. PMID 605916.
  6. Manske CL, Sprafka JM, Strony JT, Wang Y (1990). "Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography". Am J Med. 89 (5): 615–20. PMID 2239981.

Template:WH Template:WS